Norman Ng: China’s Drugmakers Close the Gap with US Big Pharma in Innovation
Norman Ng, Director of Patient Advocacy and Public Affairs at Healthcare Thinkers, shared a post on LinkedIn:
“China’s Drugmakers Close the Gap with US Big Pharma in Innovation
Chinese pharmaceutical companies are rapidly advancing in drug development, challenging the dominance of US and Western pharmaceutical giants. Leveraging increased R and D investment, government support, and a growing talent pool, firms like BeOne, Innovent Biologics, and Hengrui Pharmaceuticals are producing cutting-edge treatments, particularly in oncology and immunology.
The report highlights China’s progress in biologics and targeted therapies, as well as its expanding global clinical trials and partnerships. While US and European firms still lead in overall innovation, China’s focus on high-demand therapies and cost competitiveness positions it as a rising force in the global pharmaceutical industry. Regulatory reforms and a push for self-sufficiency in healthcare are further accelerating this trend.
Key takeaways:
- China’s biopharma sector is narrowing the innovation gap with Western rivals.
- Homegrown drugs are gaining traction domestically and internationally.
- The shift signals long-term competition for Big Pharma in pricing and market share.”
More posts featuring Norman Ng on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023